Browsing Tag
BioVie Inc.
2 posts
Platelet biomarker could shape bezisterim Phase 3 strategy after mixed investor response
Bezisterim shows broad Parkinson’s improvements, but BioVie’s stock plunge and cash needs raise doubts. Read the full Phase 2 analysis.
Why targeting ERK and NF-κB pathways may change Parkinson’s disease drug development
Discover how BioVie Inc. is targeting ERK and NF-κB pathways in Parkinson’s disease and what Phase 2 data could mean. Read the full analysis.